Inositol pyrophosphates play an important role in human pathologies such cancer, diabetes and obesity; however, the exact mechanism of action is a matter of dispute. The lack of commercially available inositol pyrophosphates renders detailed studies problematic. Here we describe a simple protocol to produce and isolate milligrams of inositol pyrophosphates.
Myo-inositol is present in nature either unmodified or in more complex phosphorylated derivates. Of the latest, the two most abundant in eukaryotic cells are inositol pentakisphosphate (IP5) and inositol hexakisphosphate (phytic acid or IP6). IP5 and IP6 are the precursors of inositol pyrophosphate molecules that contain one or more pyrophosphate bonds1. Phosphorylation of IP6 generates diphoshoinositolpentakisphosphate (IP7 or PP-IP5) and bisdiphoshoinositoltetrakisphosphate (IP8 or (PP)2-IP4). Inositol pyrophosphates have been isolated from all eukaryotic organisms so far studied. In addition, the two distinct classes of enzymes responsible for inositol pyrophosphate synthesis are highly conserved throughout evolution2-4.
The IP6 kinases (IP6Ks) posses an enormous catalytic flexibility, converting IP5 and IP6 to PP-IP4 and IP7 respectively and subsequently, by using these products as substrates, promote the generation of more complex molecules5,6. Recently, a second class of pyrophosphate generating enzymes was identified in the form of the yeast protein VIP1 (also referred as PP-IP5K), which is able to convert IP6 to IP7 and IP87,8.
Inositol pyrophosphates regulate many disparate cellular processes such as insulin secretion9, telomere length10,11, chemotaxis12, vesicular trafficking13, phosphate homeostasis14 and HIV-1 gag release15. Two mechanisms of actions have been proposed for this class of molecules. They can affect cellular function by allosterically interacting with specific proteins like AKT16. Alternatively, the pyrophosphate group can donate a phosphate to pre-phosphorylated proteins17. The enormous potential of this research field is hampered by the absence of a commercial source of inositol pyrophosphates, which is preventing many scientists from studying these molecules and this new post-translational modification. The methods currently available to isolate inositol pyrophosphates require sophisticated chromatographic apparatus18,19. These procedures use acidic conditions that might lead to inositol pyrophosphate degradation20 and thus to poor recovery. Furthermore, the cumbersome post-column desalting procedures restrict their use to specialized laboratories.
In this study we describe an undemanding method for the generation, isolation and purification of the products of the IP6-kinase and PP-IP5-kinases reactions. This method was possible by the ability of polyacrylamide gel electrophoresis (PAGE) to resolve highly phosphorylated inositol polyphosphates20. Following IP6K1 and PP-IP5K enzymatic reactions using IP6 as the substrate, PAGE was used to separate the generated inositol pyrophosphates that were subsequently eluted in water.
1. Enzymatic Reaction – day 1 (1 hour in the afternoon)
2. Polyacrylamide gel casting and loading – day 2 (4 hours in the afternoon)
3. Isolation of IP7 – day 3 (4 hours) and day 4 (6-7 hour SpeedVac drying process)
The IP7 band should be visible since it runs slightly slower than the IP6 standard. ATP, which runs faster than IP6, should also be visible (Figure 1). Transfer the stained portion of the gel in a de-staining solution (20% (w/v) methanol) for a few minutes, wash away any excess of Toluidine Blue and reposition the gel with the unstained gel.
If visualization of higher pyrophosphorylated inositol isoforms (IP8 and IP9) is required, stain the gel with Toluidine Blue staining solution for 20 minutes at room temperature. Subsequently, wash away the Toluidine Blue with the de-staining solution for about 15 minutes.
4. Determination of IP7 concentration and purity.
5. Representative Results:
The preparative enzymatic conversion of IP6 to IP7 using IP6K1 and VIP1 enzymes can be easily resolved using PAGE analysis (Figure 1). The loading of IP6 as a size control together with Toluidine Blue gel staining allows the identification of the pyrophosphorylated derivates, since they run slower depending on the number of phosphate groups present on the inositol ring. The procedure described above allows the easy purification of IP7. The analysis of the purified inositol pyrophosphate by PAGE revealed the purity of our IP7 (Figure 2A). Interestingly, the 1/3PP-IP5 isomer of IP7 product of VIP1 migrates slightly slower than the 5PP-IP5 isomer of IP7 that is generated by the IP6K1. Use of IP6 standards permit an easy quantification of the concentration of the purified IP7 (Figure 2B). Before using IP7 for further experiments, its biological activity can be assessed
(Figure 3). 5PP-IP5 is incubated with VIP1 and with the IP7 phosphatase DDP1 (diphosphoinositol polyphosphate phosphohydrolase). Routinely, the purified IP7 is converted to IP8 by VIP1 and to IP6 by DDP1 (Figure 3).
Figure 1: Toluidine staining of PAGE and isolation of the IP7 band. The portion of the gel containing the standard (IP6) was cut and stained using a Toluidine Blue solution. The three bands represent (top to bottom) IP7, IP6 and ATP. The stained portion of the gel was then aligned with the remaining of the gel. This allows the localization of the portion of the gel containing IP7, which can then be cut and purified (dashed box).
Figure 2: PAGE analysis of IP6K1 and VIP1 reaction products. A) Analysis of IP6 (4, 2, 1, 0.5 nmol) by Toluidine Blue staining was used in order to determine the IP7 concentration purified from both IP6K1 (5PP-IP5) and VIP1 (1/3PP-IP5) reactions. B) Scatter plot analysis to determine the concentration of the purified IP7. Concentrations were determined according to band intensity, calculated using imageJ software, compared to pre-determined amounts of IP6. The X-axis represents intensities; the Y-axis represents concentrations expressed in nmol.
Figure 3: Analysis of IP7 biological activity. To determine the quality of the purified IP7 we incubated 5PP-IP5 (IP6K1 generated IP7) with VIP1 or with the IP7 phosphatase DDP1 and then resolved the reaction on PAGE. The DAPI and Toluidine staining revealed the expected production of IP8 by VIP1 and the conversion of IP7 to IP6 by DDP1.
The use of inositol pyrophosphate in biochemistry is severely limited by the commercial unavailability of such compounds and the poor sensitivity of the existing detection methods. The combination of PAGE, which enables the separation of molecules possessing different number of phosphate groups, and Toluidine Blue (Figure 1), a metachromatic dye which binds to phosphate groups, enables the easy detection of inositol pyrophoshate isoforms opening new avenues of research20.
The described use of PAGE technology to purify inositol pyrophosphate products of the enzymatic reaction carried outby either IP6K1 or VIP1 is a simple, economic and reliable method that allows for the production of large amounts of high quality IP7. The method described above is not limited to the simple purification of IP7 but minor modifications of the described protocol may allow the purification of a different range of inositol pyrophosphates. Higher phosphorylated inositol pyrophosphate isoforms, containing more than eight phosphate groups can be detected using IP7 or different amounts of IP6 as a substrate20,6. These inositol pyrophosphates can be detected by increasing the length of the staining procedure and subsequently purified (section 3.2). Moreover, the use of IP5 as substrate for the enzymatic reaction would allow the purification of PP-IP5 and other inositol pyrophosphates containing a hydroxyl group on the inositol ring.
In conclusion, this undemanding method allows for the reliable purification of milligram quantities of inositol pyrophosphates with widely available instruments, thus opening new avenues for this exciting research field.
The authors have nothing to disclose.
We thank A. Riccio for helpful comments and to read the manuscript. This work was supported by the Medical Research Council (MRC) funding to the Cell Biology Unit and by a Human Frontier Science Program Grant (RGP0048/2009-C).
Name of the reagent | Company | Catalogue number |
---|---|---|
Phytic Acid (IP6) | Sigma-Aldrich | P8810 |
Poly-P (sodium hexametaphosphate) | Sigma-Aldrich | P8510 |
ATP-Mg2+ salt | Sigma-Aldrich | A9187 |
OrangeG | Sigma-Aldrich | O3756 |
PhosphoCreatine (PCr) | Sigma-Aldrich | P7936 |
CreatinePhospho Kinase (CPK) | Sigma-Aldrich | C3755 |
GST-Vip1 | 17 | 17 |
His-IP6K1 | 18 | 18 |
His-Ddp1 | Available in lab | Available in lab |
Acrylamide:Bis-Acrylamide 19:1 (40%) | Flowgen | H16972 |
Ammonium Persulfate (APS) | Sigma-Aldrich | A9164 |
Tris/Borate/EDTA (TBE) | Sigma-Aldrich | T 9060 |
Temed | BDH | 43083G |
Toluidine Blue | Sigma-Aldrich | 198161 |
SpeedVac | Christ | 100218 |
Gel apparatus | Hoefer | SE600 |
Vacuum manifold | Christ | Alpha 2-4 |
Vacuum pump | ABM Greiffenberger | 4EKF63CX |